Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P25789
UPID:
PSA4_HUMAN
Alternative names:
Macropain subunit C9; Multicatalytic endopeptidase complex subunit C9; Proteasome component C9; Proteasome subunit L
Alternative UPACC:
P25789; D3DW86; Q53XP2; Q567Q5; Q8TBD1
Background:
Proteasome subunit alpha type-4, also known as Macropain subunit C9, plays a pivotal role in the proteolytic degradation of intracellular proteins. Integral to the 20S core proteasome complex, it is crucial for maintaining cellular protein homeostasis by eliminating misfolded or damaged proteins and regulating protein levels required for cellular functions.
Therapeutic significance:
Understanding the role of Proteasome subunit alpha type-4 could open doors to potential therapeutic strategies. Its involvement in protein degradation pathways highlights its potential as a target for developing treatments aimed at diseases characterized by protein aggregation or misfolding.